ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, its associated co-morbidities, and other gastrointestinal disorders, today announced interim clinical results from the VBLOC-RF2 feasibility study of the Company’s VBLOC™ vagal blocking therapy device, the Maestro™ System.
